MTOR and prostate carcinoma: Application of dual PI3K/mTOR inhibitors, BEZ235 and PI103, in combination with IR, had shown superior anticancer efficacies and enhanced radiosensitization characterized by reduced colony-formation, G2/M cell cycle arrest, increased DNA damage, apoptosis, autophagic flux in the radioresistant prostate cancer cells (128).